| pubmed-article:18064313 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18064313 | lifeskim:mentions | umls-concept:C0062505 | lld:lifeskim |
| pubmed-article:18064313 | lifeskim:mentions | umls-concept:C0019142 | lld:lifeskim |
| pubmed-article:18064313 | lifeskim:mentions | umls-concept:C1148561 | lld:lifeskim |
| pubmed-article:18064313 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
| pubmed-article:18064313 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18064313 | pubmed:dateCreated | 2007-12-7 | lld:pubmed |
| pubmed-article:18064313 | pubmed:abstractText | A key element for the physiological restriction of blood coagulation at the endothelial cell surface is its non-thrombogenic property, mainly attributed to cell surface heparan sulfate proteoglycans. Heparanase is an endo-beta-D-glucuronidase with specific heparan sulfate degrading activity, which is produced and stored in platelets, and is released upon their activation. We examined the effects of heparanase pro-enzyme on coagulation functions, predominantly under physiological conditions. While heparanase pro-enzyme does not directly affect coagulation protein activities, it has profound effects on heparinoid-mediated regulation of coagulation responses, apparently via mechanisms that do not involve its enzymatic activity. Heparanase pro-enzyme reverses the anti-coagulant activity of unfractionated heparin on the coagulation pathway as well as on thrombin activity. In addition, heparanase pro-enzyme abrogated the factor X inhibitory activity of low-molecular-weight heparin (LMWH). The pro-coagulant effects of the non-active heparanase were also exerted by its major functional heparin-binding peptide. Finally, the effects of heparanase on the activity of factor VII activating protease that is auto-activated by heparinoids indicated a complete antagonistic action of heparanase in this system. Altogether, heparanase pro-coagulant activities that were also demonstrated in plasma samples from patients under LMWH treatment, point to a possible use of this molecule as antagonist for heparinoid treatment. | lld:pubmed |
| pubmed-article:18064313 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18064313 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18064313 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18064313 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:18064313 | pubmed:issn | 0340-6245 | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:PreissnerKlau... | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:DeutschVardaV | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:VlodavskyIsra... | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:KatzBen-ZionB... | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:HerishanuYair... | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:IlanNetaN | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:NaparstekEliz... | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:MuhlLarsL | lld:pubmed |
| pubmed-article:18064313 | pubmed:author | pubmed-author:ZwangEttyE | lld:pubmed |
| pubmed-article:18064313 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18064313 | pubmed:volume | 98 | lld:pubmed |
| pubmed-article:18064313 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18064313 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18064313 | pubmed:pagination | 1193-9 | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:meshHeading | pubmed-meshheading:18064313... | lld:pubmed |
| pubmed-article:18064313 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:18064313 | pubmed:articleTitle | Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms. | lld:pubmed |
| pubmed-article:18064313 | pubmed:affiliation | The Hematology Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv 64239, Israel. bkatz@tasmc.health.gov.il | lld:pubmed |
| pubmed-article:18064313 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18064313 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:10855 | entrezgene:pubmed | pubmed-article:18064313 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18064313 | lld:entrezgene |
